After finishing at $45.45 in the prior trading day, 10x Genomics Inc (NASDAQ: TXG) closed at $47.16, up 3.76%. In other words, the price has increased by $+1.71 from its previous closing price. On the day, 1360549 shares were traded. TXG stock price reached its highest trading level at $48.00 during the session, while it also had its lowest trading level at $44.97.
Ratios:
Our goal is to gain a better understanding of TXG by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.11 and its Current Ratio is at 4.69. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on December 14, 2023, initiated with a Buy rating and assigned the stock a target price of $60.
On December 13, 2023, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $55.
BofA Securities Upgraded its Underperform to Neutral on December 12, 2023, whereas the target price for the stock was revised from $36 to $54.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 22 when Saxonov Serge sold 2,821 shares for $46.34 per share. The transaction valued at 130,737 led to the insider holds 847,560 shares of the business.
Hindson Benjamin J. sold 2,613 shares of TXG for $121,098 on Feb 22. The insider now owns 283,059 shares after completing the transaction at $46.34 per share. On Feb 22, another insider, McAnear Justin J., who serves as the Chief Financial Officer of the company, sold 1,865 shares for $46.34 each. As a result, the insider received 86,432 and left with 95,240 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TXG now has a Market Capitalization of 5.62B and an Enterprise Value of 5.33B. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.08 while its Price-to-Book (P/B) ratio in mrq is 7.58. Its current Enterprise Value per Revenue stands at 8.61 whereas that against EBITDA is -25.97.
Stock Price History:
Over the past 52 weeks, TXG has reached a high of $63.57, while it has fallen to a 52-week low of $33.79. The 50-Day Moving Average of the stock is 48.50, while the 200-Day Moving Average is calculated to be 48.76.
Shares Statistics:
The stock has traded on average 1.26M shares per day over the past 3-months and 1.51M shares per day over the last 10 days, according to various share statistics. A total of 105.04M shares are outstanding, with a floating share count of 98.15M. Insiders hold about 17.64% of the company’s shares, while institutions hold 76.06% stake in the company. Shares short for TXG as of Jan 31, 2024 were 6.66M with a Short Ratio of 5.29, compared to 4.66M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 5.63% and a Short% of Float of 8.03%.
Earnings Estimates
Its stock is currently analyzed by 14 different market analysts. On average, analysts expect EPS of -$0.51 for the current quarter, with a high estimate of -$0.4 and a low estimate of -$0.65, while EPS last year was -$0.44. The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.36 and low estimates of -$0.59.
Analysts are recommending an EPS of between -$1.11 and -$2.29 for the fiscal current year, implying an average EPS of -$1.61. EPS for the following year is -$0.94, with 14 analysts recommending between -$0.33 and -$1.48.
Revenue Estimates
13 analysts predict $142.8M in revenue for the current quarter. It ranges from a high estimate of $145.95M to a low estimate of $139.35M. As of the current estimate, 10x Genomics Inc’s year-ago sales were $128.82M, an estimated increase of 10.90% from the year-ago figure. For the next quarter, 13 analysts are estimating revenue of $157.25M, an increase of 7.10% less than the figure of $10.90% in the same quarter last year. There is a high estimate of $163.8M for the next quarter, whereas the lowest estimate is $149.83M.
A total of 15 analysts have provided revenue estimates for TXG’s current fiscal year. The highest revenue estimate was $685.5M, while the lowest revenue estimate was $672.3M, resulting in an average revenue estimate of $678.88M. In the same quarter a year ago, actual revenue was $618.73M, up 9.70% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $795.71M in the next fiscal year. The high estimate is $863M and the low estimate is $743.9M. The average revenue growth estimate for next year is up 17.20% from the average revenue estimate for this year.
